SCHEMBL2804081

SCHEMBL2804081

O=S(=O)(c1cccc(Cl)c1Cl)N1CCc2c(cnc3[nH]ncc23)C1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 1/20 0.53
TSHR P16473 1/20 0.45
LMNA P02545 2/20 0.42
KMT2A Q03164 1/20 0.42
SGK1 O00141 3/20 0.41
CHRM1 P11229 1/20 0.39
PAK1 Q13153 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
SCN9A Q15858 1/20 0.38
AKR1C3 P42330 1/20 0.37
AKR1C2 P52895 1/20 0.37
MET P08581 2/20 0.37
FLT3 P36888 1/20 0.37
ESR1 P03372 1/20 0.36
ESR2 Q92731 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2803967 0.92 HTR6 (0.43) HTR6TSHRLMNAKMT2APAK1
SCHEMBL2803593 0.91 MAPK1 (0.46) HTR6TSHRLMNAKMT2ACHRM1
SCHEMBL2809144 0.90 HTR6 (0.43) HTR6LMNASGK1SMN1; SMN2SCN9A
SCHEMBL2803134 0.90 HTR6 (0.43) HTR6TSHRLMNAKMT2ASGK1
SCHEMBL2805453 0.89 MET (0.46) HTR6LMNAKMT2APAK1SMN1; SMN2
SCHEMBL2806857 0.84 PKM (0.48) TSHRKMT2ASGK1SMN1; SMN2
SCHEMBL2804490 0.84 HSD11B1 (0.42) HTR6TSHRKMT2APAK1SCN9A
SCHEMBL2802866 0.83 KMT2A (0.55) LMNAKMT2ASGK1SCN9A
SCHEMBL2805150 0.83 ALOX5AP (0.39) LMNAKMT2APAK1SCN9AESR1
SCHEMBL2805084 0.82 EPHX2 (0.41) HTR6SGK1AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
WO-2010078427-A1 SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 HTR6 697/4885TSHR 4751/4885LMNA 1591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.